View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Analysis
May 13, 2021updated 01 Dec 2021 1:16pm

Lilly’s partnership with Indian drugmakers will expand access to Covid-19 treatment

The pacts will increase the availability of baricitinib in India as it battles a catastrophic second wave of coronavirus.

By Darcy Jimenez

As India grapples with a devastating second wave of coronavirus, Eli Lilly has entered royalty-free, voluntary licensing agreements with six manufacturers in the country to expand the availability of baricitinib as a Covid-19 treatment.

Baricitinib received FDA emergency use authorisation for Covid-19 patients, in combination with remdesivir, in November.  This month, the drug combination was granted restricted emergency authorisation by India’s Central Drugs Standard Control Organisation for the treatment of hospitalised adults requiring oxygen or ventilation due to coronavirus.

Baricitinib, branded as Olumiant, is an oral rheumatoid arthritis drug developed by Incyte and licensed to Lilly. In 2009, the companies announced an exclusive worldwide licence and collaboration agreement for the commercialisation of baricitinib for inflammatory and autoimmune diseases.

Licensing deals have been signed with six Indian generic drugmakers so far: Cipla, Lupin, Sun Pharma, Dr. Reddy’s, MSN Laboratories and Torrent Pharmaceuticals.

Sun Pharma’s CEO of India business Kirti Ganorkar commented: “Through this collaboration, we aim to join our forces with Lilly to accelerate access to baricitinib in India at a time when it is most needed. This is another step by Sun Pharma towards making more treatment options available to patients in India for dealing with the pandemic.”

In addition to working with local pharma companies to increase the distribution of baricitinib in the country, Lilly is also offering donations of its drug to the Indian government through Direct Relief.  According to a statement made by the American company, an initial donation of 400,000 baricitinib tablets has been made immediately available for hospitalised Covid-19 patients in India, and Lilly “will work urgently to increase the quantity of donated product multi-fold over the coming weeks”.

India is among the countries worst hit by the Covid-19 pandemic, this week reaching the grim milestone of over 250,000 deaths amid severe oxygen shortages across the country’s hospitals.

Lilly India’s managing director Luca Visini said the company is “committed to supporting India in this healthcare challenge” through its pipeline of medicines.

“We are swiftly working to ensure high quality manufacturing and equitable access of baricitinib for Covid-19 in India by issuing six voluntary licences for baricitinib to pharmaceutical companies in India. This is in addition to the donations being offered by Lilly to the Indian Government.

“We will continue to explore other possible initiatives to support patients and the healthcare system in India.”

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU